The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
Open accessAbstract
Summary Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer. Here, we report updated results from an interim analysis to assess overall survival as well as invasive disease-free survival and distant relapse-free survival with additional follow-up. Methods In monarchE, an open-label, randomised, phase 3 trial, adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence with an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 603 sites including hospitals and academic and community centres in 38 countries. Patients were randomly assigned (1:1) by means of an interactive web-based response system (block size of 4), stratified by previous chemotherapy, menopausal status, and region, to receive standard-of-care endocrine therapy of physician’s choice for up to 10 years with or without abemaciclib 150 mg orally twice a day for 2 years (treatment period). All therapies were administered in an open-label manner without masking. High-risk disease was defined as either four or more positive axillary lymph nodes, or between one and three positive axillary lymph nodes and either grade 3 disease or tumour size of 5 cm or larger (cohort 1). A smaller group of patients were enrolled with between one and three positive axillary lymph nodes and Ki-67 of at least 20% as an additional risk feature (cohort 2). This was a prespecified overall survival interim analysis planned to occur 2 years after the primary outcome analysis for invasive disease-free survival. Efficacy was assessed in the intention-to-treat population. Safety was assessed in all treated patients. The study is registered with ClinicalTrials.gov, NCT03155997, and is ongoing. Findings Between July 17, 2017, and Aug 12, 2019, 5637 patients were randomly assigned (5601 [99∙4%] were women and 36 [0·6%] were men). 2808 were assigned to receive abemaciclib plus endocrine therapy and 2829 were assigned to receive endocrine therapy alone. At a median follow-up of 42 months (IQR 37–47), median invasive disease-free survival was not reached in either group and the invasive disease-free survival benefit previously reported was sustained: HR 0·664 (95% CI 0·578–0·762, nominal p<0∙0001). At 4 years, the absolute difference in invasive disease-free survival between the groups was 6·4% (85·8% [95% CI 84·2–87·3] in the abemaciclib plus endocrine therapy group vs 79·4% [77·5–81·1] in the endocrine therapy alone group). 157 (5·6%) of 2808 patients in the abemaciclib plus endocrine therapy group died compared with 173 (6·1%) of 2829 patients in the endocrine therapy alone group (HR 0·929, 95% CI 0·748–1·153; p=0·50). The most common grade 3–4 adverse events were neutropenia (in 548 [19·6%] of 2791 patients receiving abemaciclib plus endocrine therapy vs 24 [0·9%] of 2800 patients in the endocrine therapy alone group), leukopenia (318 [11·4%] vs 11 [0·4%]), and diarrhoea (218 [7·8%] vs six [0·2%]). Serious adverse events occurred in 433 (15·5%) of 2791 patients receiving abemaciclib plus endocrine therapy versus 256 (9·1%) of 2800 receiving endocrine therapy. There were two treatment-related deaths in the abemaciclib plus endocrine therapy group (diarrhoea and pneumonitis) and none in the endocrine therapy alone group. Interpretation Adjuvant abemaciclib reduces the risk of recurrence. The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer. Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine therapy in these patients. Funding Eli Lilly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., Bergh, J., Dowsett, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701830 · Cited by 1,822
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Martinez Rodriguez, J. L., Campone, M., Hamilton, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02514 · Cited by 1,022
Self-citationHammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.907 · Cited by 895
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Hammond, M. E. H., Hayes, D. F., Dowsett, M., et al. (2010) · PubMed Central · Cited by 541
Cited by
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.016 · Cited by 1,008
Self-citationBreast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C.-S., Fasching, P. A., Crown, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305488 · Cited by 405
Self-citationCyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
Metadata
- Authors
- Johnston, S. R. D., Toi, M., O'Shaughnessy, J., Rastogi, P., Campone, M., Neven, P., Huang, C.-S., Huober, J., Jaliffe, G. G., Cicin, I., Tolaney, S. M., Goetz, M. P., Rugo, H. S., Senkus, E., Testa, L., Del Mastro, L., Shimizu, C., Wei, R., Shahir, A., Munoz, M., San Antonio, B., André, V., Harbeck, N., & Martin, M.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 24
- Issue
- 1
- Pages
- 77-90
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4311018441
- Cited by
- 599
- References
- 25
- FWCI
- 67.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(22)00694-5
- The paper
- Johnston, S. R. D., Toi, M., O'Shaughnessy, J., Rastogi, P., Campone, M., Neven, P., Huang, C.-S., Huober, J., Jaliffe, G. G., Cicin, I., Tolaney, S. M., Goetz, M. P., Rugo, H. S., Senkus, E., Testa, L., Del Mastro, L., Shimizu, C., Wei, R., Shahir, A., . . . Martin, M. (2023). Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(22)00694-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.